CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2008-04-17): Caspase activity a useful marker of liver injury in chronic hepatitis B

Clinical

Caspase activity a useful marker of liver injury in chronic hepatitis B

Last Updated: 2008-04-17 16:17:35 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Serum apoptotic caspase activity is strongly associated with the presence of active liver histological lesions in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B infection, according to a recent study by Greek researchers.

The level of serum apoptotic caspase activity is also valuable, they found, for differentiating between inactive chronic HBV carriers and patients with HBeAg-negative chronic hepatitis B (CHB).

Published in the April issue of Gut, the study is reportedly the first to systematically evaluate the significance of serum apoptotic caspase activity in patients with HBeAg-negative chronic hepatitis B.

Hepatocyte apoptosis triggered by liver injury activates several cysteine-aspartate proteases, also known as caspases, which are known to cleave the cellular protein cytokeratin-18 (CK-18), the researchers explain. The study methodology used a novel ELISA that measures serum levels of CK-18 fragments, as markers for serum apoptotic caspase activity.

For the study, Dr. G. V. Papatheodoridis of the Athens University Medical School and colleagues recruited 115 consecutive treatment-naive HBV patients and 30 healthy volunteer healthcare workers as controls.

Mean CK-18 fragment levels were lowest in the healthy controls, higher in inactive HBV carriers and highest in HBeAg-negative CHB patients.

Because HBeAg-negative CHB patients with transiently normal ALT activity can easily be misclassified as inactive HBV carriers, the researchers assessed CK-18 fragment levels in this subgroup. In the 16 CHB patients with normal ALT on the day of measurement, CK-18 fragment levels were significantly higher than in inactive carriers (p = 0.001) and relatively lower than in the 46 CHB patients with increased ALT (p = 0.077).

When CK-18 levels were quantitatively assessed in the 62 CHB patients, they correlated significantly with not only ALT but also several other relevant measures, such as serum HBV DNA (p = 0.026). Overall, however, CK-18 levels did not correlate with severity of histological lesions.

The team concludes that "these data certainly deserve further evaluation and validation in larger, prospectively followed cohorts.

Gut 2008;57:500-506.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.